Answers are grounded in this paper and cite their sources.
Objective This study aimed to evaluate the preliminary efficacy and safety of combined botulinum toxin type A injection into the detrusor and pelvic floor trigger points in women with interstitial cystitis/bladder pain syndrome (IC/BPS) and concomitant pelvic floor muscle dysfunction. Methods This retrospective study analyzed IC/BPS patients hospitalized at the Urology Center of the First Affiliated Hospital of Xinjiang Medical University between January 2023 and January 2025 who underwent botulinum toxin type A injection therapy. All included patients had IC/BPS with concomitant pelvic floor muscle dysfunction, defined as elevated pelvic floor electromyographic resting activity and clinically identifiable pelvic floor tenderness/trigger points. Pelvic floor muscle dysfunction was a shared eligibility characteristic of both groups and was not used to define the comparison groups. Patients were retrospectively grouped according to the treatment strategy received in routine clinical practice: intradetrusor BTX-A injection alone (Intradetrusor-only group, n = 49) or combined intradetrusor and pelvic floor trigger-point BTX-A injection (Combined-treatment group, n = 58). Pre-and post-treatment follow-up data were evaluated, including changes in ICPI, ICSI, OABSS, pain scores, Physical Health (PH) and Mental Health (MH) scores, and psychological anxiety scores. Baseline characteristics included age, BMI, history of abdominal surgery, and changes in pain intensity (FPS-R), SF-12, HARS, and OABSS. Results Among 107 patients, baseline demographic and clinical characteristics were generally comparable between the intradetrusor-only group ( n = 49) and the combined-treatment group ( n = 58), although baseline anxiety distributions differed. In adjusted linear mixed-effects models, the combined-treatment strategy was associated with greater improvement in pain intensity at 2 weeks ( β = −0.41, 95% CI −0.78 to −0.04; P = 0.029) and a more favorable OABSS trajectory at 3 months ( β = −0.74, 95% CI −1.25 to −0.23; P = 0.004). No significant adjusted between-group differences were observed for anxiety outcomes, ICPI, ICSI, or general health measures. Conclusion In women with IC/BPS and concomitant pelvic floor muscle dysfunction, both treatment strategies were associated with clinical improvement during the 3-month follow-up. The combined-treatment strategy was associated with greater improvement in selected outcomes after adjustment for baseline covariates. However, because of the retrospective, non-randomized design, potential selection and residual confounding, different intradetrusor BTX-A doses between groups, lack of placebo control, and limited follow-up, these findings are exploratory and do not establish treatment superiority.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: